Kiran PatelVP, Medicine Development Leader, Oncology R & D GSK
Michael GottesmanChief, Laboratory of Cell Biology, and Head, Multidrug Resistance Section Center for Cancer Research NCI, NIH
Michael ZindaExecutive Director AstraZeneca
Pasi JanneAssociate Professor Harvard Medical School
After years of research and billions of dollars worth of investment cancer therapies are still failing. The major reason? Resistance.
Understanding tumor evolution and mechanisms of drug resistance is crucial for developing successful therapies. Therapies that delay the onset of resistance will have increased durability, will add more value to your pipeline and will be of greater benefit to patients.
Targeting Cancer Drug Resistance is about the approaches drug developers are taking to tackle resistance in the clinic. All to enable you to develop therapies that will overcome resistance, impact the market for longer and increase patient survival.
This meeting will arm you with information to increase the durability of drugs currently in your pipeline, as well as rationally guide future therapeutic approaches.
Hear the pioneering discoveries in tumor biology that reveal how cancer can evade current treatments, how cancer adapts, evolves and develops. Learn the translational approaches drug developers are taking to turn these discoveries into successful therapies. Apply what you’ve learnt to your own pipeline to accelerate progression of your therapies through the clinic.
This meeting provides a comprehensive investigation into all of the mechanisms for overcoming cancer drug resistance, allowing you to develop more successful, commercially viable therapies.
Attend Targeting Cancer Drug Resistance to:
Drug developers and research professionals who are dedicated to overcoming resistance through evolving their knowledge of resistance mechanisms and applying this knowledge to developing improved cancer therapies.
The following have already expressed an interest in the meeting
“Well organized. Far easier to network than at other events. Great job!" Biogen Idec
“Great to see and hear what the other pharma companies are doing” Abbott
“Very valuable and useful information. One of the best meetings I’ve ever attended.” Millennium